Ladies and gentlemen, thank you for standing by. Welcome to the 3M conference call. During the presentation, all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. At that time, if you have a question, please press the one followed by the four on your telephone keypad. It is recommended that you use a landline phone if you're going to register for a question. As a reminder, this conference is being recorded Tuesday, August 29, 2023. I would now like to turn the call over to Bruce Jermeland, Senior Vice President of Investor Relations at 3M.
Thank you, and good morning, everyone. We appreciate you joining us on short notice, as we want to share more details and answer your questions about our settlement announcement earlier this morning. With me today is Kevin Rhodes, our Chief Legal Affairs Officer. Kevin will make some formal comments, and then we'll take your questions. Please note that today's press release and slide presentation are posted on the homepage of our investor relations website at 3M.com. Please turn to slide two. Please take a moment to read the forward-looking statement. During today's conference call, we will make certain predictive statements that reflect our current views about 3M's future performance and financial results. These statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties.
Item 1A of our most recent Form 10-Q lists some of the most important risk factors that could cause actual results to differ from our predictions. Please note, the charge associated with the settlement agreement announced today will be reflected as an adjustment in arriving at 3M results adjusted for special items. With that, please turn to slide 3, and I'll now hand the call off to Kevin. Kevin?
Thank you, Bruce, and good morning, everyone. Today is an important step forward for 3M. We have entered into a settlement agreement intended to resolve the litigation and all claims involving the Combat Arms Earplugs. Before I go into details about the settlement, I want to provide some background about the Combat Arms Earplugs and the litigation. The products at issue in the litigation were developed by Aearo Technologies for the U.S. military prior to 3M's acquisition of Aearo in 2008, and were sold from 1999 until 2015. These products offer protection from high-level impulse noises, such as gunfire, while allowing users to hear lower-level sounds like speech. When used properly, the products were safe and effective for their intended purpose. However, since 2019, 3M and Aearo have faced litigation from individuals alleging hearing injury.
These claims have been centralized in a multidistrict litigation in federal court in Florida and a state court in Minnesota. As the litigation has progressed, our focus has been on achieving a full and final resolution on acceptable terms. The settlement we are announcing today is intended to do that. Now, I will provide some more detail on our agreement. Please turn to slide 4. This agreement was reached through a mediation process involving mediators appointed by the federal and state courts and the negotiating plaintiffs' counsel appointed by the courts. The agreement is structured to promote participation by claimants and to help provide greater certainty and finality for all involved. To be clear, the parties that worked in the mediation, 3M and Aearo, the courts, and the plaintiffs' counsel, are committed to the successful implementation of the agreement.
The agreement specifies total consideration of $6 billion, payable from 2023 to 2029, and is comprised of $5 billion in cash and $1 billion worth of 3M common stock. The total pre-tax present value of the agreement is $5.3 billion. The company will record a pre-tax charge of approximately $4.2 billion in the third quarter of 2023, representing the $5.3 billion pre-tax present value of the agreement, net of 3M's existing accrual of approximately $1.1 billion related to this matter. This charge will be reflected as an adjustment in arriving at 3M's results, adjusted for special items. 3M is actively engaged in insurance recovery activities, and Aearo initiated an insurance recovery litigation against its carriers in June related to the Combat Arms litigation. This agreement is not an admission of liability.
3M is prepared to continue to defend itself in the litigation if certain terms in the settlement agreement are not fulfilled. Now, please turn to slide 5 for more details about the agreement structure and anticipated payment schedule. The settlement is structured to promote claimant participation and is intended to achieve a full and final resolution of all claims and cases. The parties and courts will work together to implement the agreement, including reaching the claimant participation levels set forth in the agreement that trigger the payments summarized here. Initial payments that will be made through the end of this year are expected to total up to $660 million. These payments are intended to resolve all adverse trial verdicts, as well as bellwether cases and the federal and state cases that are the furthest along under the court's scheduling orders.
Also, the payments will fund the expedited releases of certain claims. After that, there's a series of payments contingent on reaching specific participation levels. This structure is designed to help promote participation by all claimants. Once 98% of claimants join the settlement, that triggers $3.5 billion in payments that 3M is scheduled to make between 2024 and 2027, pursuant to the payment schedule set forth in the agreement. We anticipate that the payments will include a mix of cash and 3M common stock. The use of stock in this agreement will be subject to a hearing, which we anticipate the MDL court will hold before the end of the year. This proceeding is specifically focused on the use of 3M common stock as a form of consideration provided to fund the settlement fund. This hearing is not for approval of the settlement agreement.
Beyond the 98% participation level, as higher claimant participation levels are met, additional payments are triggered. The agreement is structured for payments of up to $1 billion in 2026, $100 million in 2028, and $100 million in 2029, provided the specified participation levels are met. In addition, the agreement specifies further payments from 2026 to 2029, structured as finality and reserve fund payment. The specific conditions for triggering those payments are confidential under court order, but as explained in the settlement agreement, it is the parties' goal to resolve all Combat Arms claims, including those potentially that may be filed in the future. The finality payments are made in 2026 and 2027, and the reserve fund includes payments up to $550 million.
For any claimants that choose to continue to litigate and not accept the settlement, the courts will establish a comprehensive process, including hearings, mandatory mediation, and orders setting out the fact and expert evidence required to proceed. The courts have indicated that they intend to keep this process in place until 2031. Now, please turn to slide 6. This slide lays out the anticipated payment schedule under the agreement as set forth in its terms. This schedule reflects the earliest anticipated payment dates based on reaching participation levels. However, it is important to note that payments will be made according to the schedule, not when the participation level is reached. The schedule shown here reflects the initial payments of up to $660 million this year, and the next payments, beginning in 2024, are contingent upon achieving the 98% claimant participation level.
Those payments and the others I discussed on the previous slide are anticipated to proceed as shown here, with payments continuing on the agreed-upon schedule until 2029. Next slide, please. This slide shows the next steps for implementing the settlement agreements for the remainder of 2023. As I mentioned, the courts are entering case management orders to support implementation of the settlement. The identification of claimants and notification of their opportunity to participate in the settlement can also begin immediately. On September 8, a $10 million payment will be made to set up the settlement administration process. The MDL court has indicated that it will also hold a hearing expected to be on that same date, which is another opportunity to provide public notice of the agreed-upon settlement terms.
The initial payments I discussed to resolve cases and release certain claims in 2023 are scheduled to be made in the third and fourth quarters. We estimate that the court hearing that is specific to the use of 3M common stock to fund a portion of the settlement will take place on or about December 1. In closing, the Combat Arms settlement agreement announced today, along with the previously announced PFAS Public Water System settlement agreement, demonstrates our continued focus on managing litigation. Regarding the public water system settlement, we have resolved questions raised by state attorneys general about certain provisions of the settlement agreement, and they have withdrawn their objections.
Subject to the PFAS MDL court approval, the amended agreement preserves 3M's intention to benefit U.S.-based public water systems nationwide that provide drinking water to the vast majority of Americans, resolve ongoing litigation, and release from potential future litigation, all at the previously announced present value cost of $10.3 billion, payable over 13 years. With today's Combat Arms settlement and the settlement agreement with the public water systems, we continue to take steps forward to address litigation risk and focus on driving business performance. Thank you all again for being on the call today, and now Bruce and I will be happy to take your questions.
Ladies and gentlemen, if you would like to register a question using a landline phone, please press the one followed by the four on your telephone keypad. You will hear a three-tone prompt to acknowledge your request. If your question has been answered and you would like to withdraw your registration, please press the one followed by the three. If you are using a speakerphone, please lift your handset before entering your request. Please limit your participation to one question and one follow-up. One moment, please, while we compile the Q&A roster. Our first question comes from Julian Mitchell with Barclays. You may proceed with your question.
Hi, good morning, and congratulations on getting to this settlement point. Maybe just any context would be welcome, Kevin or Bruce, around the equity portion of the settlement, the sort of thinking behind that $1 billion in 3M common stock. You know, the company isn't highly levered in any way. So just maybe some thoughts from your side, and if it's possible to speak on behalf of any of the plaintiffs in terms of sort of how you got to that $1 billion number, and why there is an equity portion.
Yeah, sure. Happy to talk about that. So just as a reminder, so the overall transaction is structured to include $6 billion of payments through 2029, and that includes the $5 billion in cash and $1 billion in 3M common stock, subject to the approval process, that I talked about this morning. So that results in the overall pre-tax present value of $5.3 billion. So relative to the use of equity, you know, I can-- what I can say is this overall terms of the agreement were reached through the confidential mediation process that we previously disclosed that was underway. And in those discussions, the terms were reached with plaintiff's counsel.
You know, beyond that, I can't go into the specifics of the negotiations, but I can say that we were pleased to reach terms acceptable to all parties, and those terms included the equity component of the consideration that's being provided. You know, I should note, as well, that our current plan of record is to issue the equity subject to the conditions that I mentioned. But if anything changes, we can always reevaluate that plan. We have retained, under the agreement, the right to substitute an equivalent value in cash for any of the equity payments.
I see, but just my, my follow-up would just be around the fact that it, you know, investors and shareholders shouldn't look at that $1 billion equity number and think, "Oh, this must signify some concerns, you know, from the 3M management team around the, the sort of future balance sheet leverage," you know, what that might mean for the dividend payout schedule. You know, that, that was sort of where I was coming from.
No, I wouldn't say characterize it in any way like that. I would say that it was a product of terms that were discussed and desired and agreed to in a negotiation. And, importantly, we have retained that flexibility to make cash payments. So we'll see how circumstances develop, and that ability to substitute cash is unfettered under the agreement. So, we'll keep track of that and decide what to do at the appropriate time.
Great. Thank you, and, thanks for hosting this call.
Yeah, thanks, Stuart.
You're welcome.
Our next question comes from Joe Ritchie with Goldman Sachs. You may proceed with your question.
Hi, good morning, everybody, and, yeah, congratulations on getting to this point, regarding the litigation. Just, maybe my first question is just focused on the claimant participation threshold and specifically the denominator. How locked in is the denominator to that equation? And specifically, you know, can future claimants, you know, participate in this settlement? How does that actually work?
Yeah. So in the, in the, in a general sense, you, when you think about the claimant participation level, the numerator would be the number of claimants who are participating in the settlement or who have had the case, their cases dismissed. And then the denominator is the total claimant population. So as we work through the settlement, that denominator will be defined by providing lists of current claims, current, you know, known claimants who haven't yet filed. And there'll be a process where that information is gathered. It will proceed over the next 4 months, and then there's a 2-month extension after the initial registration date to a final registration date, where the participation threshold will be calculated.
Initially, you know, that deadline can be extended, but after that, the agreement does contemplate that future claims will come in and can be addressed under the terms of the agreement. So those future claims would be added into the denominator, whether they come in during that six-month period I talked about or thereafter. And as they come in, they would factor into the calculation of the claimant participation level.
Got it. Okay, that's super helpful. And then I guess just my follow-on question is, you kind of think about the cash portion of the payment for 2024. If you combined, you know, this amount, you know, called roughly $650 million, plus the amount that was contemplated under the public water utility, you know, settlement, I'm just wondering, are there any thoughts at this point on how that's gonna be funded? And then specifically, you know, the cash that's on the balance sheet today, how much of that cash is actually restricted versus free and available to fund those two payments?
... Joe, I'm gonna turn that one over to Bruce, but before I do, I just wanted to mention that we did file a Form 8-K with the SEC this morning, and an exhibit to that form includes the full—all of the full settlement agreements, along with their exhibits, with the exception of a couple confidential exhibits under a court sealing order. But that does lay out the full payment schedule, and that's Exhibit One to the master settlement agreement. So I did wanna make that note for the record and now turn it over to Bruce.
Yeah, Joe, relative to funding, the payments related to this agreement, along with the public water supplier agreement, you know, first and foremost, obviously, the strength of the 3M business model generates strong, robust cash flow. In addition, as we have discussed, for much of the past year, we have obviously the intended spin of healthcare, that's pending. Upon spin, we anticipate to lever the business 3-3.5 times, which will provide a one-time payment to 3M. And then also 3M intends to retain 19.9% minority equity position that provides additional financial flexibility. And then finally, as you note, 3M does have a very strong capital structure, so that also provides flexibility.
So the combination of all those factors, we believe, provide good financial flexibility to address the payment schedule for both the public water system settlement, along with the Combat Arms settlement.
Okay, great. Very helpful. Thank you. Thank you, both.
Yeah, you're welcome.
You're welcome.
Our next question comes from Deane Dray with RBC Capital Markets. You may proceed with your question.
Thank you. Good morning, everyone. Appreciate all the color this morning.
Good morning, Deane.
Good morning.
Hey, just can we first question would be on your insurance assets. There was a filing last year that said you had two carriers, one at $550 million and another just over $1 billion. Where do those stand? And you said that you made those filings earlier. Just your expectations, how contentious will that be? And just any color there would be helpful.
Yeah, thanks for the question, Deane. So, yeah, those filings that you referenced were for a portion of the coverage that Aearo has as a legacy coverage, and then the 3M coverage, and both of those are coverage that we're seeking to access to offset a portion of the cost of these agreements. So as I mentioned, we've been in discussions, both 3M and Aearo, and we're at the early stages of those discussions. Aearo has also filed suit in June in Delaware court to seek determination of coverage under its policy.
So, early in the process, but we are moving forward and all of our carriers are on notice, and we've begun those discussions, and in the case of Aearo, initiated action, and we'll continue to move through that process and provide updates as we go.
Great, that's helpful. And just, on the PFAS side, just a couple updates, if we could. The initial agreement included 19 utilities, drinking water utilities out of the 15,000 in the U.S. Do you have any update? And I know there's an automatic opt-in, but any update on either how many utilities have notified you they will not participate? Just your sense there and what the timing is. And then lastly, anything on plans for addressing the wastewater plants, and their damages and costs, as well as product liability, and anything on the international front would be helpful.
Yeah, so as I mentioned earlier in my opening remarks, the process thus far under the public water system settlement has involved addressing questions that were raised by the state attorneys general's offices. We've addressed those. As I mentioned, they have withdrawn their objections, so we're now in a position the parties believe the settlement is fair for the class members, and the overall agreement is now before the MDL court for preliminary approval. So as to your question about opt-outs, the process hasn't really begun yet. It will begin after the preliminary approval.
We believe that will take place over a several-month period to a final approval, and at that point, we'll know where we are in terms of any opt-outs and take action depending on what we learn through that process. You know, with respect to that resolution, it's certainly an important step forward for 3M. Drinking water claims have been a major focus of the PFAS litigation to date, and the public water systems cases constitute a significant portion of our PFAS litigation docket. Other parts of the docket, you mentioned the wastewater and personal injuries, some of the other claims, they're not as advanced. Those will continue to progress. That will take time...
Every docket of cases is based on its own particular facts and legal theories, and so it will take time to work through those, and many of those are only at the very earliest stages. You mentioned international, that's one that will take additional time to work through as well. So it'd be premature at this point to talk about you know how those might be resolved or when, but we-- what I can say is that we'll continue to address the remainder of the PFAS docket by defending ourselves in court or through negotiated resolutions, all as appropriate, and we'll continue to share information as we can in our SEC filings.
Thank you.
Our next question comes from Joseph O'Dea with Wells Fargo. You may proceed with your question.
Hi, good morning. Thanks for taking my questions.
Hi, Joe. Morning.
Hi. First, on Combat Arms, just, you know, under a scenario where you don't get the 98% participation level in 2024, you know, how does that play out? You know, I thought you commented that the funding was sort of structured at this point, so you would continue to fund, even if it's not at that level, but just under that kind of scenario, how we should think about how things play out.
Yeah. So let me start by saying that our intent, and I think, the intent of everyone certainly who's been involved in that process to date, is to reach the 98% participation level, as well as the higher participation levels that I talked about earlier. The parties and the courts will be working together to provide an opportunity for all claimants to participate, and the courts will play a key role in that process through the case management orders that were entered this morning and are being entered to help implement the settlement process. The 98% threshold, you know, is the threshold to trigger all of the payments that we talked about in 2024. So, the only payments that are...
that I talked about that wouldn't be subject to that or the other thresholds is that $660 million in 2023 for the verdict and wave cases, the administrative expenses, and some early claims releases. The rest are contingent on the 98% or the higher thresholds, so the payments would not continue in 2024 unless and until that threshold is met, and they wouldn't become due. As soon as the threshold was met, they'd be on the schedule set forth in exhibit one of the agreement.
So there is an opt-out right at the, if the 98% isn't reached, and we'll, we would address that, if we came to it, but at this point, it's certainly our intent, and I think everyone's intent who's been involved in this process, to hit that 98% threshold and the other ones as well.
Then on the public water suppliers and the sort of opposition from attorneys general, can you just expand a little bit on sort of the core elements of that opposition? It seems like that was resolved rather quickly, and so kind of what was discussed, what was resolved there?
Yeah. There were some questions raised about the scope and the intent of the agreement. I think the updated agreement clarifies and certainly reaffirms the parties' intent that the agreement is intended to support funding for PFAS remediation for public water systems nationwide that provide drinking water to the vast majority of Americans. The present value pre-tax of that agreement is $10.3 billion over 13 years, so none of that has changed in the agreement. And, you know, I'd refer you to the court filings that were just made that have the specifics of some of the clarifying amendments that were made to the agreement, and that amended agreement is what's now before the MDL court for preliminary approval.
I appreciate it. Thank you.
Our next question comes from Jeff Sprague, with Vertical Research Partners. You may proceed with your question.
Thank you. Good morning.
Good morning.
First, just kind of back to the equity component. Appreciate the color about the optionality to give, you know, to switch it to cash. But, clearly, you must have had the desire or the need to, you know, kind of hedge yourself here with the equity. So could, could you just kind of address that a little bit? And then what, what is the nature of the requirement from the court to use equity? Does that somehow hinge on your financial metrics or something else? Is there some kind of evaluation, you know, associated with, you know, the safety, stability of the equity that's part of the court decision-making process there?
Yeah. So let me... Well, I'll start with the first part of the question, and I'll say that, you know, it was just, you know, I really said what I can. The mediation process and the discussions that went into it are confidential. I would say that, you know, when you think about the equity component of the settlement around with, along with the optionality to substitute cash, it provides, you know, optionality there, and we'll continue to look at those options as we move forward. So, really, we'll have to stay with that on the first part of your question. On the second part of your question, it doesn't have to do anything with the value of the company or anything like that.
It has to do with an exemption to registering the stock prior to putting it into the Qualified Settlement Fund, so under SEC law, and part of that, establishing entitlement to that exemption, and being authorized to provide the stock to the fund as a court hearing, just to ascertain whether it's fair to provide equity as its component to the settlement funding. You know, if that were not to take place and we weren't able to get the exemption, we would, again, have the option to substitute cash for that equity. So, it's not a question of the entire deal being contingent on that.
It's just a formality or a technicality for issuing stock to help to fund the settlement.
Then, maybe just as a follow-up, I kind of back to Joe's question about 98% participation. So if I, if I understand, you know, the nine or 10 cases that you've lost, that, you know, $10s of millions of dollars a piece, are gonna stand, and you're gonna make those payments, that, correct me if I'm wrong on that, but that would seem to be a pretty strong motivation for less than 98% of people to get on board this, right? I'm sure not all these claims are as legitimate, you know, they're not all equally legitimate, I suppose, in some respects, although you probably can't address that point.
But again, just the dollars that have, you know, been found against you would seem to really mitigate against, you know, claimants getting on board at, you know, net of legal fees and everything is actually gonna be a fairly small amount of money if we're dividing this by 300,000 some odd, you know, plaintiffs.
Well, I would say that as we've disclosed previously, there have been extensive negotiations around this deal. It's been subject to a mediation process for many months. Participants have included, you know, both 3M and Aearo, but also the plaintiffs' negotiating counsel, which were appointed by the courts, both the federal and state courts, to represent the interests of the claimants. And the structure of the terms of the deal reflect the agreement that was reached, and the parties are aligned in terms of implementing the settlement successfully and providing that path to a full and final resolution. And these are the terms that were deemed to be appropriate to put us on that path.
Okay, thank you.
Our next question comes from Chris Snyder with UBS. You may proceed with your question.
Thank you. You know, I wanted to follow up on some of the communication around the dividend, as that's, you know, the biggest investor incoming this morning. You know, in addition to the litigation payouts between the earplugs and PFAS, you know, you're also obviously spinning out healthcare, which is a, you know, maybe 30-35% of company EBITDA. Can you just talk about, you know, how the company views the dividend, you know, as it stands today? Obviously, 6% yield probably, you know, maybe wasn't intended to be at that level. Thank you.
Yeah, Chris. If you think about our capital allocation priorities for 3M, they remain unchanged. Our first priority remains investing in the business because that's where we generate our strongest returns. Secondly, certainly, 3M has a long history of paying a dividend, and we expect that to be a priority for the company as we move forward. Thirdly is to pursue strategic M&A to augment our organic growth strategies. And then finally, share repurchase is the last priority. You know, relative to the dividend, you know, as I mentioned, that is an important aspect of our capital allocation priorities. At the end of the day, the dividend is a decision of the board of directors.
you know, it's up to them to determine what they think the appropriate level of the dividend for the company to be going forward.
Thank you. That was it for me. Appreciate it.
Yeah.
Our next question comes from Nigel Coe with Wolfe Research. You may proceed with your question.
Thanks. Good morning, everyone.
Morning, Nigel.
Morning. I just want to go back to Jeff's question about the incentives for you know, rogue you know, attorneys or those who feel that they've got a genuine hearing loss and decide to see litigation. Are there... I mean, I haven't gone through the 8-K filing this morning, but are there guardrails in place to try and get these folks back into the settlement or mediation? I mean, what kind of defenses do you have to prevent you know, another wave of litigation outside of this settlement?
So the settlement is structured, as I mentioned earlier, to incent full participation, so to provide options for expedited early releases and then the additional payments at the participation levels. You know, having said that, if claimants wish to continue to litigate and not to participate in the settlement, there is a process that's being put into place. It's being implemented by the court's case management orders that are being entered by the federal and state courts to help administer the settlement, and that will include early case evaluation hearings, a mediation process, and a process for gathering fact and expert evidence to support the claims.
And after working through that process, the claimants who nonetheless choose not to participate can eventually pursue their claims through litigation, but the agreement also provides mechanisms to resolve those claims as well as time goes on. So certainly, you know, contemplate incentives for full participation, but claims that continue to be litigated will be part of the process that the courts are implementing with their orders today.
Okay, great. And my follow-up question is: Can you just confirm that or not that these payments will be eligible for tax deduction? And you know, now that we've got some crystallized you know payment schedules for both the water settlement and the-
... Combat Arms, do you expect healthcare, the healthcare spin to absorb some of those payments, or will that be outside of this settlement?
Yeah, Nigel, we do believe that the payments will be tax-deductible as they're paid. So, as Kevin mentioned, the pre-tax present value is $5.3 billion, so you'd have to adjust for the tax impact.
Yeah, and these settlements are contemplated to be with Parent Co. So, the Combat Arms liability and the legacy PFAS liability is being retained by Parent Co. post-spin.
Great. Thank you.
You're welcome.
Our next question comes from Stephen Tusa with J.P. Morgan Securities. You may proceed with your question.
Well, hi, good morning. Thanks for taking my questions. This is Pat Baumann for Stephen Tusa. First one is just in terms of the timing of this agreement, did it just comes on the heels, obviously, of the June, I think it was the June agreement for the PFAS with the public water authorities. Did the timing of that settlement have anything to do with the timing of this agreement? Did the negotiations accelerate, you know, as a result of that PFAS settlement?
No, I would say the timing more reflects our commitment to proactively manage litigation, to look for opportunities to resolve cases where appropriate. We've been focused on that for both of the dockets that we've talked about this morning for some time, and the settlements came together at roughly the same time. But that's more a product of our engagement in seeking resolution opportunities, not any more direct linkage than that.
Great. And then one follow-up is on mechanics of the way that you're presenting the pre-tax discounted value. So the discount rate I think you used for the PFAS settlement was 5.2%, you know, per your 10-Q filing. What's the discount rate you're using for this particular agreement? And then why are you using the discount rate that you're using?
Yeah, Pat, so relative to the discount rate, it is 5.6%. We engage with external institutions, taking a look at the interest rate relative to each of the years that the payments will be made over. So that 5.6% represents a weighted average of the payment schedule as we laid out in today's slide deck. So the rate was determined through external engagement with external parties.
The 5.6% includes the cost of equity in that number?
Yeah, it's a balance over that payment period.
Okay. Thanks so much for the time.
Yeah.
Best of luck.
Our next question comes from Vlad Bystricky with Citigroup. You may proceed with your question.
Good morning, guys.
Hey, Vlad.
Thanks for hosting the call, and thanks for hosting the call and all the information. Just quickly for me, have you had, you know, ahead of, ahead of this announcement, have you had conversations with the credit ratings agencies? And can you talk about any indications they've given of how this settlement, you know, following the PFAS one, could impact their view on 3M's credit rating going forward?
Yeah, Vlad, we do have regular and ongoing discussions, with the rating agencies, similar that we have with our equity investors. You know, ultimately, the rating of 3M is up to the rating agencies, not up to 3M. So but we do have regular and ongoing, conversations with them. So, what they ultimately do with the rating is their decision.
Okay, understood. Thanks, Bruce. And then maybe just a last quick one from me. On the potential insurance recoveries and insurance claims that you filed, is the $1.5 billion in claims kind of the maximum in insurance recoveries that you could potentially get, or are there any other, you know, pools of available coverage or other recovery mechanisms potentially available?
Yeah, we're still working through that process. There is, you know, those policies that were referenced earlier were ones that had been discussed as part of the settlement negotiations and there are... We're still working through what other availability there might be. So, that will develop over time as we work through the recovery efforts. And, you know, the agreement provides that we'll be providing recoveries as part of the funding with some backstops in place over time as we work through that process.
All right, great. Thanks, Kevin`.
Yep.
Our last question comes from Lawrence Alexander with Jefferies. You may proceed with your question. Mr. Alexander, your line is open. You may proceed with your question.
Sorry about that. This is Dan Rizzo for Lawrence. I was on mute.
Hey, Dan.
Everything's been answered, so I just have a really quick question. Somebody mentioned 300,000 plaintiffs outstanding for this. I thought the number was closer to 200,000. I just want a little bit of clarification on what we're talking about here.
Yeah, I think you know, the numbers change frequently. I think the latest numbers that I saw for active plaintiffs, I think, was about 246,000 in the federal MDL, so thereabouts. But of course, it changes as time goes on, and we'll be, as we implement the settlement, we'll be working through the process of cataloging all of the numbers and making sure that we've got the full total.
All right. Thank you very much.
Ladies and gentlemen, that does conclude the conference call for today. We thank you for your participation, and we ask that you please disconnect your lines.